Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia

被引:287
作者
Mueller, Beat
Harbarth, Stephan
Stolz, Daiana
Bingisser, Roland
Mueller, Christian
Leuppi, Joerg
Nusbaumer, Charly
Tamm, Michael
Christ-Crain, Mirjam
机构
[1] Univ Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[2] Univ Hosp, Div Hosp Epidemiol, CH-1211 Geneva, Switzerland
[3] Univ Hosp, Dept Pneumol, CH-4031 Basel, Switzerland
[4] Univ Hosp, Emergenyc Dept, CH-4031 Basel, Switzerland
[5] Univ Hosp, Dept Clin Chem, CH-4031 Basel, Switzerland
关键词
D O I
10.1186/1471-2334-7-10
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Community-acquired pneumonia (CAP) is the most frequent infection-related cause of death. The reference standard to diagnose CAP is a new infiltrate on chest radiograph in the presence of recently acquired respiratory signs and symptoms. This study aims to evaluate the diagnostic and prognostic accuracy of clinical signs and symptoms and laboratory biomarkers for CAP. Methods: 545 patients with suspected lower respiratory tract infection, admitted to the emergency department of a university hospital were included in a pre-planned post-hoc analysis of two controlled intervention trials. Baseline assessment included history, clinical examination, radiography and measurements of procalcitonin (PCT), highly sensitive C-reactive protein (hsCRP) and leukocyte count. Results: Of the 545 patients, 373 had CAP, 132 other respiratory tract infections, and 40 other final diagnoses. The AUC of a clinical model including standard clinical signs and symptoms (i.e. fever, cough, sputum production, abnormal chest auscultation and dyspnea) to diagnose CAP was 0.79 [ 95% CI, 0.75-0.83]. This AUC was significantly improved by including PCT and hsCRP (0.92 [0.89-0.94]; p < 0.001). PCT had a higher diagnostic accuracy (AUC, 0.88 [0.84-0.93]) in differentiating CAP from other diagnoses, as compared to hsCRP (AUC, 0.76 [0.69-0.83]; p < 0.001) and total leukocyte count (AUC, 0.69 [0.62-0.77]; p < 0.001). To predict bacteremia, PCT had a higher AUC (0.85 [0.80-0.91]) as compared to hsCRP (p = 0.01), leukocyte count (p = 0.002) and elevated body temperature (p < 0.001). PCT, in contrast to hsCRP and leukocyte count, increased with increasing severity of CAP, as assessed by the pneumonia severity index (p < 0.001). Conclusion: PCT, and to a lesser degree hsCRP, improve the accuracy of currently recommended approaches for the diagnosis of CAP, thereby complementing clinical signs and symptoms. PCT is useful in the severity assessment of CAP.
引用
收藏
页数:10
相关论文
共 39 条
[1]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[2]   Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa -: Incidence, risk, and prognosis [J].
Arancibia, F ;
Bauer, TT ;
Ewig, S ;
Mensa, J ;
Gonzalez, J ;
Niederman, MS ;
Torres, A .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (16) :1849-1858
[3]   Outpatient care compared with hospitalization for community-acquired pneumonia -: A randomized trial in low-risk patients [J].
Carratalà, J ;
Fernández-Sabé, N ;
Ortega, L ;
Castellsagué, X ;
Rosón, B ;
Dorca, J ;
Fernández-Agüera, A ;
Verdaguer, R ;
Martínez, J ;
Manresa, F ;
Gudiol, F .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (03) :165-172
[4]   Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:: cluster-randomised, single-blinded intervention trial [J].
Christ-Crain, M ;
Jaccard-Stolz, D ;
Bingisser, R ;
Gencay, MM ;
Huber, PR ;
Tamm, M ;
Müller, B .
LANCET, 2004, 363 (9409) :600-607
[5]   Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia a Randomized trial [J].
Christ-Crain, Miriam ;
Stolz, Daiana ;
Bingisser, Roland ;
Muller, Christian ;
Miedinger, David ;
Huber, Peter R. ;
Zimmerli, Werner ;
Harbarth, Stephan ;
Tamm, Michael ;
Mueller, Beat .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (01) :84-93
[6]  
Dalhoff K, 2001, INT J ANTIMICROB AG, V18, pS39, DOI 10.1016/S0924-8579(01)00405-8
[7]   Clinical trial registration - A statement from the International Committee of Medical Journal Editors [J].
DeAngelis, CD ;
Drazen, JM ;
Frizelle, FA ;
Haug, C ;
Hoey, J ;
Horton, R ;
Kotzin, S ;
Laine, C ;
Marusic, A ;
Overbeke, AJPM ;
Schroeder, TV ;
Sox, HC ;
Van der Weyden, MB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1363-1364
[8]   Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial [J].
Evans, AT ;
Husain, S ;
Durairaj, L ;
Sadowski, LS ;
Charles-Damte, M ;
Wang, Y .
LANCET, 2002, 359 (9318) :1648-1654
[9]   Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced Amoxicillin-Clavulanate (2,000/125 milligrams) versus those of Amoxicillin-Clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults [J].
File, TA ;
Lode, H ;
Kurz, H ;
Kozak, R ;
Xie, H ;
Berkowitz, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3323-3331
[10]   A prediction rule to identify low-risk patients with community-acquired pneumonia [J].
Fine, MJ ;
Auble, TE ;
Yealy, DM ;
Hanusa, BH ;
Weissfeld, LA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Kapoor, WN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250